iBio, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
iBio appointed Dr. Molly Carr as Chief Medical Officer effective July 31, 2026, reporting to CEO Martin Brenner. She received an inducement grant of 430,000 nonqualified stock options at $1.40/share (grant-date closing price), vesting 25% after one year, then 6.25% quarterly thereafter. Base salary: $475,000/year; target bonus 40% of base; severance upon termination without cause or good-reason resignation: 9 months base salary + pro-rata bonus + COBRA; upon change-of-control termination: 12 months base salary + full target bonus + accelerated equity vesting.
Why this rating
CMO hire with relevant endocrinology expertise supports clinical advancement, but hire costs (~$475K base + ~$190K target bonus + option value) are modest relative to ~$22.4M market cap (~3% annual opex impact). Routine executive appointment; no material contract, financing, or pipeline change disclosed.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.